Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy
Recruiting in Palo Alto (17 mi)
+18 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Quigley Pharma, Inc.
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo.
Research Team
PR
Philip Raskin, MD
Principal Investigator
University of Texas, Southwestern Medical Center at Dallas
Eligibility Criteria
Inclusion Criteria
diagnosis of diabetic neuropathy
must have some pain daily in the lower limbs due to diabetic polyneuropathy for at least 3 months prior to enrollment
must be willing to comply with study directions, write information in a diary (such as pain medications taken), read and comprehend written instructions, complete questionnaires, and have the ability to apply the cream as directed
Treatment Details
Interventions
- QR-333 (Other)
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: QR-333Active Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Land Clinical StudiesWest Caldwell, NJ
UT Southwestern Medical Center at DallasDallas, TX
Rainier Clinical Research Center, IncRenton, WA
dgd ResearchSan Antonio, TX
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Quigley Pharma, Inc.
Lead Sponsor
Trials
1
Patients Recruited
140+